SCHEMBL5864062

SCHEMBL5864062

Cc1cc(C)c(S(=O)(=O)N(Cc2cccc(O)c2)c2ccc(/C=C/C(=O)N3CCCC3)cc2)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
GPR183 P32249 3/20 0.42
APP P05067 2/20 0.41
ALDH1A1 P00352 4/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
POLB P06746 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
PELI1 Q96FA3 2/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5864066 1.00 MAPT (0.43) MAPTGPR183APPALDH1A1KMT2A
SCHEMBL5863737 0.86 AKR1C3 (0.41) MAPTALDH1A1LMNAKEAP1
SCHEMBL5863735 0.86 AKR1C3 (0.41) MAPTALDH1A1LMNAKEAP1
SCHEMBL5864174 0.84 NR1H4 (0.48) KEAP1
SCHEMBL5864173 0.84 NR1H4 (0.48) KEAP1
SCHEMBL5863982 0.82 MAPT (0.37) MAPTGPR183APPALDH1A1KMT2A
SCHEMBL5864243 0.79 ALDH1A1 (0.47) ALDH1A1KMT2ASMN1; SMN2KDM4ELMNA
SCHEMBL5864248 0.79 ALDH1A1 (0.47) ALDH1A1KMT2ASMN1; SMN2KDM4ELMNA
SCHEMBL5863828 0.79 GPR55 (0.42) MAPTALDH1A1LMNAKEAP1
SCHEMBL5863833 0.79 GPR55 (0.42) MAPTALDH1A1LMNAKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053212-B2 Acyclic amide and sulfonamide ligands for the estrogen receptor PFIZER INC. (US) 2006-05-30 US disclosed
EP-1542967-A1 AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR Pfizer Products Inc. (US) 2005-06-22 EP disclosed
US-20040110767-A1 Acyclic amide and sulfonamide ligands for the estrogen receptor PFIZER INC 2004-06-10 US disclosed
WO-2004026823-A1 AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR PFIZER PRODUCTS INC. (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110767-A1 Acyclic amide and sulfonamide ligands for the estrogen receptor GHSR, GPER1, SSTR1 MAPT 4755/4885GPR183 147/4885APP 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.